1.Brief Introduction on Clinical Pharmacists in Taiwan Region and Their Pharmaceutical Work
Qingmin YANG ; Yan XIAO ; Tiebing SONG
China Pharmacy 2001;0(08):-
OBJECTIVE:To promote the development of clinical pharmacy.METHODS:The clinical pharmacists and the status quo of pharmaceutical care in Taiwan region were introduced.RESULTS&CONCLUSION:The clinical pharmaceutical care mode prevalent in Taiwan region can serve as a model for mainland China to follow.What is urgent now is to emphasis the cultivation of clinical pharmacists and to perfect the concept of pharmaceutical care.
2.Role of ERK/AP-1 pathway in the differentiation induced by DADS on human gastric caner cell
Hui LING ; Ying SONG ; Tiebing ZENG ; Jingping YUAN ; Qi SU
Chinese Pharmacological Bulletin 2003;0(11):-
AIM To investigate the role of ERK/AP-1 pathway in the differentiation induced by diallyl disulfide (DADS) on human gastric cancer MGC803 cell. METHODS Immunocytochemical staining and morphometric quantitative analysis detected the expression of c-fos and c-jun;Western Blot which measured the activation of ERK was analyzed to elucidate the possible mechanism of DADS-induced human gastric cancer cell differentiation. RESULTS Immunocytochemical staining and morphometric quantitative analysis indicated that expression of c-fos and c-jun reduced(P
3.Therapeutic effect analysis of tirofiban treatment on acute coronary syndrome in elderly patients
Hui WANG ; Mei SONG ; Zhaoyang XUE ; Zhijian YANG ; Tiebing ZHU ; Liansheng WANG ; Min LU ; Ning ZHANG ; Wei LI ; Kejiang CAO
Chinese Journal of Geriatrics 2010;29(11):927-931
Objective To explore the curative effect of tirofiban treatment on high-risk acute coronary syndromes (ACS) in elderly patients receiving an early percutaneous coronary intervention (PCI) treatment. Methods The 162 elderly cases including unstable angina pectoris and non-ST -segment elevation myocardial infarction (NSTEMI) undergoing early PCI were enrolled in this study.And they were assigned to early treatment group (n=82) and deferred selective group (n=80)according to the time of using tirofiban (Gp Ⅱ b/Ⅲ a inhibitor) treatment. The effectiveness of either strategic option on tissue-level perfusion was evaluated using the TIMI myocardial perfusion grade (TMPG) before and immediately after PCI. The corrected TIMI frame count (cTFC) was also used to assess coronary artery flow and myocardial perfusion. Bleeding complications and the composite end point events at 30 days were also evaluated. Results Of all the 162 patients, the TMPG 0-1 perfusion was observed in 65 patients (40.1%). The TMPG 0-1 perfusion was significantly less frequent in early treatment group (32.9%) than in deferred selective group (47.5%) before PCI (x2=3.58, P<0.05); while the results of TIMI grade 0-1 flow (26.8% vs. 25.0%) and cTFC levels (34.2±11.8 vs. 34. 9±12. 7) before PCI were similar between the two groups (x2 =0. 07, P=0.47; t= 0.13, P=0.71, respectively). No differences were seen both in composite end point events at 30 days and bleeding complications (x2 = 0.31, P>0.05; x2=0.004, P>0. 05). Conclusions High -risk ACS patients treated with an early invasive strategy, routine upstream use of tirofiban are associated with improved tissue-level perfusion before PCI and does not increase bleeding complications when bleeding risks are carefully evaluated before enrollment.